本法律意见书所认定的事实真实、准确、完整，所发表的结论性意见合法、准确，不 存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任，但不对会议所审议 的议案内容和该等议案中所表述的事实或数据的真实性和准确性发表意见。 本法律意见书仅用于为公司本次股东会见证之目的，不得用于其他任何目的或用 途。本所及本所律师同意公司将本法律意见书作为公司本次股东会的公告材料，随其 他需公告的信息一起向公众披露，并依法对本所在其中发表的法律意见承担法律责任。 北京观韬（杭州）律师事务所 关于浙江康恩贝制药股份有限公司 2026 年第一次临时股东会的法律意见书 致：浙江康恩贝制药股份有限公司 北京观韬（杭州）律师事务所（以下简称"本所"）接受浙江康恩贝制药股份有 限公司（以下简称"公司"）的委托，指派律师列席并见证了公司 2026 年第一次临 时股东会（以下简称"本次股东会"），现依据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》，以及中国证券监督管理委员会（以 下简称"中国证监会"）发布的《上市公司股东会规则》（以下简称"《股东会规则》"）、 《上市公司治理准则》（以下简称"《治理准则》"）等法 ...

证券代码：600572 证券简称：康恩贝 公告编号：2026-013 一、会议召开和出席情况 （一）股东会召开的时间：2026 年 2 月 9 日 （二）股东会召开的地点：杭州市滨江区滨康路 568 号康恩贝中心会议室 （三）出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 532 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 949,535,644 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 37.4418 | （四）表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况 等。 浙江康恩贝制药股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次会议是否有否决议案：无 本次股东会由浙江康恩贝制药股份有限公司（以下简称"公司"）董事会召 集，因董事长出差在外，会议由公司副董事长金军丽主持。本次股东会采取现场 ...

Summary of Key Points from Conference Call Records Industry Overview 1. PCB (Printed Circuit Board) - The PCB sector has shown weak performance since Q4 of last year, primarily due to divergent market views on orthogonal backplane solutions, with some believing they may be replaced by copper cables/CPO or delayed until 2028. However, the orthogonal backplane is currently progressing steadily and is expected to enter mass production in H2 2027. Leading companies are experiencing stock price stagnation due to these divergences, highlighting their cost-effectiveness. Recommended companies include Dongshan Precision, Shenghong Technology, and Huidian Co. [1] - The CoWoP (Chip on Wafer on PCB) solution has stronger certainty, can reduce costs, improve efficiency, and bypass the shortage of substrate capacity. The value per square meter of PCB may increase several times, potentially reaching tenfold, with product launches expected by the end of 2027 and full implementation in 2028. Recommended companies in this direction include Pengding Holdings, Shennan Circuit, and Xinsong Technology. [1] 2. Storage - Contract prices remain in an upward cycle despite fluctuations in spot prices. Module companies are expected to see explosive Q1 performance, with Jiangbolong and Demingli realizing low-priced inventory. Recommended design companies include Zhaoyi Innovation (with a profit expectation of 6 billion) and Puran Co., Beijing Junzheng, and Hengshuo Co. [2] - Demand for memory modules is driven by AI servers and general servers, with recommendations for Lanke Technology (long-term profit of 10 billion) and Jucheng Co. (long-term profit of 1.5 billion). [2] 3. Communication - The recent decline in optical modules is related to the pullback of US tech stocks and speculation around CPO concepts. However, industry sources (such as Coherent and Xuchuang) indicate that CPO's potential to replace optical modules in ScaleOut scenarios is low, suggesting that short-term speculation may be excessive. [2] - North American cloud service providers have exceeded capital expenditure guidance for 2026 (620 billion, up 65% year-on-year), indicating potential accelerated demand for optical modules in 2027. Key upcoming catalysts include Nvidia's quarterly report (February 26), GTC conference (March), and OFC exhibition (NPO product showcase). Recommended companies include Zhongji Xuchuang, Xinyisheng, and Dongshan Precision. [2] - For copper connections as a Plan B alternative to orthogonal backplanes, companies to watch include Luxshare Precision, Wokai Nuclear Materials, and Huiju Technology (with potential for stock doubling). [2] - The price of scattered fiber has surged in the short term (from 25 to 50 yuan), but the low willingness of operators to raise prices raises doubts about long-term sustainability. [2] 4. Computing - Domestic computing resources are in short supply, with the recent downtime of Qianwen highlighting the scarcity of AI foundational resources. The demand for CPUs is expected to rise due to increased usage of agents compared to chatbots. Recommended companies include Haiguang Information (benefiting from both CPU and GPU), Cambrian (leading domestic AI chip manufacturer), and Tianshu Zhixin (expected to accelerate integration with leading players). [2] - Cloud infrastructure resources are expected to benefit from price increases, with recommendations for Kingsoft Cloud, Wangsu Technology, and Fourth Paradigm. [2] - In the AI application sector, the recent drop in overseas software and restructuring of SaaS business models may lead to a narrative reversal with the launch of native agent products in Q3 2026. Companies to watch include Alibaba for 2C entry reconstruction and third-party AI agents like TaxFriend, Zhongkong Technology, and Dingjie Smart. [2] 5. Media - Tencent has faced a decline due to market concerns over potential tax increases on internet platforms, although there is no space for increased game value-added tax. The company remains recommended despite rumors of Q4 earnings downgrades, maintaining a PE ratio of 15 times, which still offers value. [3] - The download situation for the Yuanbao app remains stable, and Tencent's AI capabilities may be closing the gap with larger competitors. [3] - In gaming, companies with upcoming catalysts such as Giant Network and Perfect World are recommended for short-term focus, while Century Huatong and Kaiying Network are suggested for medium to long-term attention due to expected catalysts. [3] - Tencent's establishment of a separate AI comic app is beneficial for the production side, which is entering a period of profitability. Recommendations include Kuaishou, Huanrui, and Rongxin. [3] 6. Pharmaceuticals - Attention is drawn to the update of the essential drug catalog, which may accelerate progress. [4] - The probability of inclusion in the essential drug catalog is high for unique products, with several specific products from companies like Jichuan Pharmaceutical and Panlong Pharmaceutical being highlighted. [4] - Emphasis on the global competitiveness of the innovative drug industry chain, with a focus on new-generation ADCs, IOs, small nucleic acids, and CGT. Recommended companies include Kanghong, Yingen, Yunding, and Chengdu Xian Dao. [4] - The brain-computer interface theme is noted, with a potential showcase of non-invasive products during the Spring Festival and a semi-invasive product approval for Borui Kang in March. [4] - Recommendations include Meihua Medical, Dongwei Semiconductor, and Sanbo Brain Science. [5] - The surgical robot sector is expected to see comprehensive implementation of charging policies before August, with overseas orders doubling and maintaining high growth in 2027. Key types include laparoscopic and orthopedic robots, with strong overseas performance for laparoscopic robots. Recommended companies include MicroPort, Jingfeng Medical, Tianzhihang, and Sanyou Medical. [6]

证券日报网讯2月6日，康恩贝（600572）在互动平台回答投资者提问时表示，截至2026年1月31日，公 司股东总户数为80956户。 ...

Core Viewpoint - Kangnbei (600572.SH) announced a significant share reduction by shareholder Hu Jiqiang, impacting the overall shareholding structure of the company [1] Group 1: Shareholder Activity - Hu Jiqiang reduced his shareholding by 23,854,500 shares between January 27 and February 5, 2026, at an average price of 4.529 CNY per share [1] - The reduction represents 0.941% of the company's total share capital of 2,536,084,741 shares as of February 5, 2026 [1] - Following the reduction, Hu Jiqiang and Kangnbei Group's combined shareholding decreased from 246,364,056 shares to 222,509,556 shares, lowering their ownership percentage from 9.714% to 8.774% [1]

一、信息披露义务人及其一致行动人的基本信息 （一）身份类别 证券代码：600572 证券简称：康恩贝 公告编号：2026-012 浙江康恩贝制药股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少☑ | | --- | --- | --- | --- | | 权益变动前合计比例 | 9.714% | | | | 权益变动后合计比例 | 8.774% | | | | 本次变动是否违反已作出的承诺、意 | 是□ | 否☑ | | | 向、计划 | | | | | 是否触发强制要约收购义务 | 是□ | 否☑ | | 投资者及其一致行动人的身份 □控股股东/实际控制人及其一致行动人 ☑其他 5%以上大股东及其一致行动人 □合并口径第一大股东及其一致行动人（仅适用于无控股股 东、实际控制人） □其他______________（请注明） （二）信息披露义务人信息 | 信息披露义务人名称 | | 投资者 ...

Core Viewpoint - The company announced that shareholder Hu Jiqiang reduced his stake in the company through a centralized bidding transaction, selling 23,854,500 shares at an average price of 4.529 yuan per share, which represents a reduction of 0.941% in his holdings [1] Summary by Categories Shareholder Activity - Hu Jiqiang, due to funding needs for his controlled business, sold 23,854,500 shares of the company [1] - The average selling price was 4.529 yuan per share [1] - The reduction in shareholding percentage was 0.941% [1] Ownership Structure - Following the reduction, Hu Jiqiang and his concerted party, Kang En Bei Group, saw their combined shareholding decrease from 9.714% to 8.774% [1] - The change in equity ownership reached a threshold of 1% [1] Impact on Company - The share reduction does not trigger a mandatory tender offer [1] - There will be no impact on the company's governance structure or ongoing operations [1] - The controlling shareholder and actual controller will remain unchanged [1]

Core Viewpoint - Zhejiang Kangnbei Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of TFA003 tablets, aimed at treating diabetic nephropathy [1][2]. Group 1: Drug Clinical Trial Approval - The drug TFA003 is classified as a traditional Chinese medicine under categories 2.1 and 2.3, with the application for clinical trials focusing on oral administration for diabetic nephropathy [1][2]. - The approval notice indicates that the drug meets the requirements for drug registration and can proceed with clinical trials after refining the trial protocol [1]. Group 2: R&D Status - The company has invested approximately RMB 29.57 million in the research and development of TFA003, which has shown significant efficacy in improving renal function indicators in animal studies [2]. - The drug has the potential to be developed as a new traditional Chinese medicine for diabetic nephropathy, showing improvements in glomerular filtration and renal tubular reabsorption functions [2]. Group 3: Market Situation - There are currently few drugs available for the treatment of diabetic nephropathy in both domestic and international markets, primarily relying on antihyperglycemic and antihypertensive medications [3][4]. - The market for traditional Chinese medicine related to diabetic nephropathy is projected to reach a total sales volume of RMB 27 billion in 2024, reflecting a year-on-year growth of 5.25% [6].

Group 1 - The core point of the article is that Kang En Bei announced the approval of its subsidiary's clinical trial for TFA003 tablets by the National Medical Products Administration [2] Group 2 - Kang En Bei's wholly-owned subsidiary, Hangzhou Kang En Bei Pharmaceutical Co., Ltd., received the clinical trial approval notice for TFA003 tablets [2]

Core Viewpoint - Kang En Bei (600572.SH) has received approval from the National Medical Products Administration for the clinical trial of TFA003 tablets, which are intended for the treatment of diabetic kidney disease [1] Company Summary - Kang En Bei's wholly-owned subsidiary, Hangzhou Kang En Bei Pharmaceutical Co., Ltd., has been granted the Clinical Trial Approval Notice for TFA003 tablets [1] - The approval indicates that TFA003 tablets meet the registration requirements for pharmaceuticals as per the relevant regulations [1] - The clinical trial is set to proceed after further refinement of the clinical trial protocol [1]